Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDAer Eyes Improvements In Anticoagulant Trial Design

01 May 2012

• By Bridget Silverman

Related Content

<em>Eliquis</em> Delay Fuels Speculation About Advisory Committee Meeting

01 Mar 2012

<em>Xarelto</em> Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed

01 May 2012

Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label

02 Apr 2012

Related Companies

Johnson & Johnson

Bayer AG

Boehringer Ingelheim GmbH

Bristol Myers Squibb Company

Pfizer Inc.

Additional Topics

Clinical Trials Approvals BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.